Roche Collaborates with Tempest to Evaluate TPST-1120 in a Combination Study as 1L Treatment for Hepatocellular Carcinoma

 Roche Collaborates with Tempest to Evaluate TPST-1120 in a Combination Study as 1L Treatment for Hepatocellular Carcinoma

Roche Collaborates with Tempest to Evaluate TPST-1120 in a Combination Study as 1L Treatment for Hepatocellular Carcinoma

Shots:

  • The companies collaborated to evaluate TPST-1120 + Tecentriq (atezolizumab) and Avastin (bevacizumab) in P-Ib/II study in ~60 patients with advanced HCC prior not treated with HCC
  • Tempest will retain the global rights to develop & commercialize TPST-1120 while Roche will manage the study operations for a global study
  • TPST-1120 is a first-in-class selective PPAR⍺ antagonist with a two-pronged mechanism designed to target both tumor cells directly and suppressive immune cells in the tumor microenvironment. In extensive non-clinical studies, TPST-1120 as a monothx. or in combination with other drugs resulted in reductions of tumor growth and stimulation of durable anti-tumor immunity

Click here ­to­ read full press release/ article | Ref: Globe Newswire | Image: Business Wire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post